Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2016, Article ID 7802967, 5 pages
http://dx.doi.org/10.1155/2016/7802967
Review Article

HLA Haplotype Mismatch Transplants and Posttransplant Cyclophosphamide

Istituto di Ematologia, Universita’ Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Gemelli, Rome, Italy

Received 16 November 2015; Revised 11 February 2016; Accepted 14 March 2016

Academic Editor: Suparno Chakrabarti

Copyright © 2016 Andrea Bacigalupo and Simona Sica. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Lorentino, F. Ciceri, M. Labopin et al., “HLA disparities impact on utcomes after unmanipulated haploidentical hematopoietic stem cells transplantation (HaploSCT) in Acute Leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT),” Blood, vol. 126, article 399, 2015. View at Google Scholar
  2. Y. Reisner, N. Kapoor, D. Kirkpatrick et al., “Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells,” Blood, vol. 61, no. 2, pp. 341–348, 1983. View at Google Scholar · View at Scopus
  3. F. Aversa, A. Tabilio, A. Terenzi et al., “Successful engraftment of T-cell-depleted haploidentical ‘three-loci’ incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum,” Blood, vol. 84, no. 11, pp. 3948–3955, 1994. View at Google Scholar · View at Scopus
  4. F. Locatelli, A. Bauquet, G. Palumbo, F. Moretta, and A. Bertaina, “Negative depletion of α/β+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation,” Immunology Letters, vol. 155, no. 1-2, pp. 21–23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. D.-P. Lu, L. Dong, T. Wu et al., “Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation,” Blood, vol. 107, no. 8, pp. 3065–3073, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. P. V. O'Donnell, L. Luznik, R. J. Jones et al., “Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide,” Biology of Blood and Marrow Transplantation, vol. 8, no. 7, pp. 377–386, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. G. W. Santos and A. H. Owens Jr., “Production of graft-versus-host disease in the rat and its treatment with cytotoxic agents,” Nature, vol. 210, no. 5032, pp. 139–140, 1966. View at Publisher · View at Google Scholar · View at Scopus
  8. S. R. McCurdy, J. A. Kanakry, M. M. Showel et al., “Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide,” Blood, vol. 125, no. 19, pp. 3024–3031, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Raiola, A. Dominietto, A. Ghiso et al., “Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning,” Biology of Blood and Marrow Transplantation, vol. 19, no. 1, pp. 117–122, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Bacigalupo, A. Dominietto, A. Ghiso et al., “Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update,” Bone Marrow Transplantation, vol. 50, supplement 2, pp. S37–S39, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Castagna, R. Crocchiolo, S. Furst et al., “Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide,” Biology of Blood and Marrow Transplantation, vol. 20, no. 5, pp. 724–729, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. S. R. Solomon, C. A. Sizemore, M. Sanacore et al., “Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors,” Biology of Blood and Marrow Transplantation, vol. 21, no. 7, pp. 1299–1307, 2015. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Bashey, X. Zhang, C. A. Sizemore et al., “T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation,” Journal of Clinical Oncology, vol. 31, no. 10, pp. 1310–1316, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Cieri, R. Greco, L. Crucitti et al., “Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells,” Biology of Blood and Marrow Transplantation, vol. 21, no. 8, pp. 1506–1514, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Grosso, S. Gaballa, O. Alpdogan et al., “A two-step approach to myeloablative haploidentical transplantation: low nonrelapse mortality and high survival confirmed in patients with earlier stage disease,” Biology of Blood and Marrow Transplantation, vol. 21, no. 4, pp. 646–652, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Wang, D.-H. Liu, K.-Y. Liu et al., “Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia,” Cancer, vol. 119, no. 5, pp. 978–985, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. S.-Q. Ji, H.-R. Chen, H.-M. Yan et al., “Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies,” Bone Marrow Transplantation, vol. 36, no. 4, pp. 349–354, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Di Bartolomeo, S. Santarone, G. De Angelis et al., “Unmanipulated bone marrow transplantation from haploidentical related donors for patients with high risk hematologic malignancies,” Blood, vol. 116, abstract 2350, 2010. View at Google Scholar
  19. J. Bolaños-Meade, E. J. Fuchs, L. Luznik et al., “HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease,” Blood, vol. 120, no. 22, pp. 4285–4291, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. S. O. Ciurea, M.-J. Zhang, A. A. Bacigalupo et al., “Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia,” Blood, vol. 126, no. 8, pp. 1033–1040, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. A. M. Raiola, A. Dominietto, C. di Grazia et al., “Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts,” Biology of Blood and Marrow Transplantation, vol. 20, no. 10, pp. 1573–1579, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. N. Kekre and J. H. Antin, “Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist,” Blood, vol. 124, no. 3, pp. 334–343, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Di Stasi, D. R. Milton, L. M. Poon et al., “Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors,” Biology of Blood and Marrow Transplantation, vol. 20, no. 12, pp. 1975–1981, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Bashey, X. Zhang, K. Jackson et al., “Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index,” Biology of Blood and Marrow Transplantation, vol. 22, no. 1, pp. 125–133, 2016. View at Google Scholar
  25. Y. Luo, H. Xiao, X. Lai et al., “T-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCT,” Blood, vol. 124, no. 17, pp. 2735–2743, 2014. View at Publisher · View at Google Scholar · View at Scopus
  26. J. A. Kanakry, Y. L. Kasamon, C. D. Gocke et al., “Outcomes of related donor HLA-Identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma,” Biology of Blood and Marrow Transplantation, vol. 19, no. 4, pp. 602–606, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. J. R. Passweg, H. Baldomero, P. Bader et al., “Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants,” Bone Marrow Transplantation, vol. 50, no. 4, pp. 476–482, 2015. View at Publisher · View at Google Scholar · View at Scopus